Notably, we identified dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, and tanespimycin, a heat shock protein (HSP) inhibitor, as potential candidate drugs for treating AD targeting RHBDF2 and TNFRSF10B. The gene discussed is HSP90B2P; the disease is Alzheimer disease.